https://www.selleckchem.com/pr....oducts/gsk923295.htm
anced RCC from the U.S. payers' perspective. This was the first study to examine the cost-effectiveness of pembrolizumab plus axitinib versus sunitinib in advanced renal cell carcinoma (RCC). This study found that first-line treatment with pembrolizumab plus axitinib is a cost-effective strategy when the value of willingness-to-pay is from $100,000 to $150,000 per quality-adjusted life-year in patients with advanced RCC from the U.S. payers' perspective. Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally agg
Like
Comment
Share
